CV Therapeutics, Inc.
CV Therapeutics Reports 2007 First Quarter Financial Results
Published in Drug Law Weekly, May 8th, 2007
For the quarter ended March 31, 2007, the Company reported a net loss of $55.1 million, or $0.93 per share. This compares to a net loss of $70.5 million, or $1.57 per share, for the same quarter in 2006 and to a net loss of $68.1 million, or $1.18 per share, for the prior quarter ended December 31, 2006.
For the quarter ended March 31, 2007, the Company recorded $12.0 million of net product sales for sales of Ranexa(R) (ranolazine extended-release tablets), which represents an increase of 33 percent compared to the $9.0 million of net product...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2007-05-08)
More Articles from Drug Law Weekly
- Allergies
Allergy & Asthma Network Mothers of Asthmatics Exposes Potentially Dangerous Asthma Medications - Arthritis
Former Building Cleaner Confronts J&J About Access to Health Care, Drugs - Biotech Business
Spherix Signs Letter of Intent for the Sale of Its Information Subsidiary - Drug Delivery
OctoPlus obtains full rights to PolyActive drug delivery technology from IsoTis - Drug Development
Express Scripts' Workers' Compensation Program Increases Use of Generic Drugs - Drug Development
Recent studies from National Board of Forensic Medicine add new data to drug development - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
